Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL189603 | 0.85 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL3687959 | 0.84 | PIK3CG (0.43) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL14053016 | 0.83 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188600 | 0.82 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL14053095 | 0.82 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188531 | 0.81 | PIK3CD (0.69) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188336 | 0.79 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL21036414 | 0.79 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL16029977 | 0.79 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188775 | 0.79 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |